title: [Experimental autoimmune encephalomyelitis: crosstalk with immunology and therapy].
abstract: The immune network is a complex system comprising several types of inflammatory and regulatory cells. Autoimmune diseases occur because of dysregulation in host defenses caused by a cellular imbalance. The pattern of imbalance depends on the disease. Most autoimmune diseases are chronic, and the mechanism underlying this chronic nature is yet to be determined. Monoclonal antibody therapy is highly specific to the molecules targeted and is therefore highly effective. However, this therapy cannot be applied to all autoimmune diseases, since even the most effective therapy is incapable of completely inhibiting disease activity. Antigen-specific therapies have the ability to inhibit disease activity; however, their application is limited because of the presence of various disease-specific antigens. Regulatory cell therapies also have potential, but pose a plasticity problem. By focusing our research on experimental autoimmune encephalomyelitis (EAE), which is a multiple sclerosis (MS) model and normally initially has a relapse or remission course, followed by a progressive course, we can develop alternative therapies for the treatment of autoimmune diseases by exploring the mechanism of relapse and remission. It is safe to say that immunologic history is paced with EAE on which autoimmune disease therapy is based.
authors: Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry.
authors: Youwei
authors: Y
authors: Lin
authors: Sachiko
authors: S
authors: Miyake
authors: Takashi
authors: T
authors: Yamamura
mesh_terms: D000818:Animals; D000941:Antigens / Q000276:immunology; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000628:therapy*; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology; D009479:Neuropeptides / Q000276:immunology; D012008:Recurrence
chemical_list: D000941:Antigens; D009479:Neuropeptides